Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2011-11-21Clinical Trial Update: HDCT and Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma [Phase 2]
This is a Phase 2 trial evaluating high-dose chemotherapy and stem cell transplantation for mantle cell lymphoma and relapsed low-grade non-…
-
CLINICAL_TRIALS trial_result · 2011-11-02Clinical Trial Update: Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma [Phase 2]
Phase 2 study of Zevalin (yttrium-ibritumomab tiuxetan) for relapsed or refractory mantle cell lymphoma has completed.
-
CLINICAL_TRIALS research · 2011-09-13Clinical Trial Update: Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL) [Phase 1, Phase 2]
Clinical trial update on first-line dexamethasone, ofatumumab, and bendamustine (DOT) for mantle cell lymphoma in Phase 1/2, with the trial …
-
CLINICAL_TRIALS trial_result · 2011-06-29Clinical Trial Update: Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies [Phase 2]
Phase II study assessing AT-101 as a single-agent therapy in relapsed or refractory B-cell malignancies has completed, reporting safety and …
-
CLINICAL_TRIALS trial_result · 2011-05-30Clinical Trial Update: 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma [Phase 2]
The National Cancer Institute completed a Phase 2 trial of tanespimycin (17-AAG) in relapsed or refractory Anaplastic Large Cell Lymphoma, M…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2011-03-25Clinical Trial Update: Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma [Phase 1, Phase 2]
A phase 1/2 clinical trial is evaluating the combination of bortezomib, fludarabine, and cyclophosphamide for recurrent mantle cell lymphoma…
-
CLINICAL_TRIALS withdrawal · 2011-03-16Clinical Trial Update: Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL) [Phase 1, Phase 2]
A Phase 1/2 clinical trial of bendamustine plus temsirolimus for relapsed or refractory mantle cell lymphoma has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2011-02-21Clinical Trial Update: Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 study evaluating oblimersen sodium in combination with rituximab for recurrent B-cell non-Hodgkin lymphoma completed, with results…
-
CLINICAL_TRIALS trial_result · 2011-02-15Clinical Trial Update: Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma [Phase 2]
Phase II study of VcR-CVAD with rituximab consolidation and maintenance for untreated mantle cell lymphoma has completed with results posted…
-
FDA approval · 2010-10-12FDA Approved: REVLIMID — Supplemental Application (Celgene Corporation)
FDA approved a supplemental application for REVLIMID (lenalidomide) submitted by Celgene Corporation.
-
CLINICAL_TRIALS trial_result · 2010-07-22Clinical Trial Update: Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma [Phase 2]
The Phase 2 clinical study of SyB L-0501 in patients with indolent B-cell non-Hodgkin's lymphoma and mantle cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2010-05-06Clinical Trial Update: A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation [Phase 2]
Phase 2 study evaluating Lupron Depot to enhance immune function after bone marrow transplantation was terminated, with results posted in 20…
-
CLINICAL_TRIALS withdrawal · 2010-04-22Clinical Trial Update: Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma [Phase 1]
A Phase 1 study of MDX-1411 for relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma has been withdrawn from the trial p…
-
FDA approval · 2010-02-26FDA Approved: TREANDA — Supplemental Application (Cephalon, LLC)
The FDA approved a supplemental application for TREANDA (bendamustine hydrochloride) from Cephalon, LLC, enabling revisions to its labeling …
-
CLINICAL_TRIALS research · 2009-07-27Clinical Trial Update: Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma [Phase 2]
A Phase 2 prospective trial investigates immunochemotherapy followed by autologous and allogeneic stem cell transplantation in patients with…
-
CLINICAL_TRIALS trial_result · 2009-02-12Clinical Trial Update: Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years [Phase 2]
Completed Phase 2 trial evaluating treatment at diagnosis for mantle cell lymphoma in patients under 65.
-
FDA approval · 2008-06-20FDA Approved: VELCADE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for Velcade (bortezomib) submitted by Takeda Pharmaceuticals America, Inc.
-
CLINICAL_TRIALS trial_result · 2008-02-11Clinical Trial Update: VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
This document reports results from a Phase 2 clinical trial of Velcade (bortezomib) in patients with relapsed or refractory mantle cell lymp…
-
CLINICAL_TRIALS trial_result · 2008-01-15Clinical Trial Update: Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial of elsamitrucin (SPI 28090) for relapsed/refractory non-Hodgkin's lymphoma has completed enrollment/status. The update does no…
-
CLINICAL_TRIALS research · 2006-10-18Clinical Trial Update: Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma [Phase 2]
This is a Phase 2 clinical trial update for the BORID regimen (bortezomib, rituximab, and dexamethasone) in relapsed/refractory mantle cell …
-
FDA approval · 2006-05-31FDA Approved: VELCADE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for Velcade (bortezomib) submitted by Takeda Pharmaceuticals America, Inc.